Contact Us
Drug Search Results
More Filters [+]

Lanopepden

Alternative Names: lanopepden, gsk-1322322, gsk1322322, gsk 1322322
Latest Update: 2019-01-15
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Deformylase Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lanopepden

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Skin Diseases, Bacterial|Communicable Diseases|Cellulitis|Skin Diseases, Infectious

Phase 1: Healthy Volunteers|Respiratory Tract Infections|Ranula

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
PDF112163

P1

Withdrawn

Healthy Volunteers

2015-03-01

PDF112166

P1

Withdrawn

Healthy Volunteers

2014-12-01

NCT01818011

P1

Terminated

Ranula|Respiratory Tract Infections

2013-10-18

22%
NCT01663389

P1

Completed

Healthy Volunteers

2012-10-05

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions